title: Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.
abstract: We report efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years post-vaccination. The study was conducted in a population (N=433) of women enrolled in Brazilian centres from an initial placebo-controlled study. Women were aged 15-25 years at first vaccination. During the most recent year of follow-up, approximately 7 years after initial vaccination, no cases of infection or cytohistological lesions associated with HPV-16/18 were observed in the vaccinees. Vaccine efficacy (95% confidence interval) up to 7.3 years was 94.5% (82.9, 98.9) for incident infection, 100% (55.7, 100) for 12-month persistent infection and 100% (-129.8, 100) for cervical intraepithelial neoplasia grade 2+. Antibody titres for total IgG and neutralising antibodies remained several folds above natural infection levels and >or=96% of women were seropositive. Vaccine safety was similar to placebo. This is the longest follow-up study for a licensed cervical cancer vaccine.
authors.affiliation: Hospital de Clinicas da Universidade Federal do Parana, Setor de Infecçoes em Ginecologia e Obstetrícia, Curitiba, Paraná, Brazil. newtonsdc@gmail.com
authors.forename: N
authors.initials: N
authors.lastname: De Carvalho
authors.forename: J
authors.initials: J
authors.lastname: Teixeira
authors.forename: C M
authors.initials: CM
authors.lastname: Roteli-Martins
authors.forename: P
authors.initials: P
authors.lastname: Naud
authors.forename: P
authors.initials: P
authors.lastname: De Borba
authors.forename: T
authors.initials: T
authors.lastname: Zahaf
authors.forename: N
authors.initials: N
authors.lastname: Sanchez
authors.forename: A
authors.initials: A
authors.lastname: Schuind
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D001938:Brazil; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008050:Lipid A / Q000031:analogs & derivatives; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D019496:Cancer Vaccines; D007074:Immunoglobulin G; D008050:Lipid A; D053918:Papillomavirus Vaccines